South Korea's first HIV-1/2 test to replace imports:
This article was originally published in Clinica
Korea Green Cross has developed South Korea's first test for HIV-1/2, says Pharma Koreana. Production for the domestic market is due to begin shortly, replacing some Won 2,000 million ($2.6 million) of tests which are imported annually. Jointly developed by teams from Seoul National University's Genetic Engineering Institute and the Korea Institute of Science and Technology, Genedia HIV-1/2 is a third-generation ELISA-based test.
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.